
Palleon Pharmaceuticals and Henlius Collaborate on Glycan Editing for Autoimmune Diseases
Palleon Pharmaceuticals, a leader in glyco-immunology drug development for autoimmune diseases and cancer, has announced a collaboration and licensing agreement with Shanghai Henlius Biotech, Inc. (2696.HK). The agreement focuses on the development and commercialization of Palleon’s novel human sialidase enzyme…













